Infliximab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Infliximab
   1. Pharmacist Assessment Report
   2. Infliximab: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Infliximab: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Infliximab, so there is currently no new predicted indication. The recorded uses of this drug are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	8
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
ankylosing spondylitis	licence in another country
crohn disease	licence in another country
psoriasis	licence in another country
psoriatic arthritis	licence in another country
rheumatoid arthritis	licence in another country
ulcerative colitis	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
crohn’s colitis
inflammatory bowel disease

Australia Market Information

Licence	Product	Dosage form	Status
10057H	Inflectra	Powder for I.V. infusion 100 mg	Valid

Safety Considerations

• Drug Interactions: 100 interactions were identified in total. The main ones include:
  • Major: corticosteroids (hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone including ophthalmic), deferiprone, and the radiopharmaceuticals iobenguane (I-131), ibritumomab tiuxetan and tositumomab (I-131).
  • Moderate: metronidazole, tinidazole, naltrexone, rosuvastatin, simvastatin.
  • Minor: zinc salts (sulfate, acetate, gluconate).
• Class considerations noted in the literature: serious infection risk, tuberculosis reactivation, infusion-related anaphylaxis with anti-infliximab antibodies, and paradoxical vasculitis.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---